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Background: SUMO-activating enzyme subunit 2 (SAE2) is the sole E1-activating enzyme required for numerous
important protein SUMOylation, abnormal of which is associated with carcinogenesis. SAE2 inactivation was recently
reported to be a therapeutic strategy in cancers with Myc overexpression. However, the roles of SAE2 in small cell
lung cancer (SCLC) are largely unknown.
Methods: Stably SAE2 knockdown in H446 cells were established with a lentiviral system. Cell viability, cell cycle,
and apoptosis were analyzed using MTT assay and flow cytometric assay. Expression of SAE2 mRNA and protein
were detected by qPCR, western blotting, and immunohistochemical staining. Cell invasion and migration assay
were determined by transwell chamber assay. H446 cells with or without SAE2 knockdown, nude mice models
were established to observe tumorigenesis.
Results: SAE2 was highly expressed in SCLC and significantly correlated with tumorigenesis in vivo. Cancer cells
with RNAi-mediated reduction of SAE2 expression exhibited growth retardation and apoptosis increasing. Furthermore,
down-regulation of SAE2 expression inhibited migration and invasion, simultaneously increased the sensitivity of H446
to etoposide and cisplatin.
Conclusions: SAE2 plays an important role in tumor growth, metastasis, and chemotherapy sensitivity of H446 and is a
potential clinical biomarker and therapeutic target in SCLC with high c-Myc expression.
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Lung cancer is the first leading cause of cancer-related
deaths in males while second in females all over the world
[1, 2]. Small cell lung cancer (SCLC) accounts for 13 % of
all newly diagnosed cases of lung cancer worldwide, re-
presenting approximately 180,000 cases per year [3–5].
Patients at extensive stage have median survival of 7–12
months, and 5-year survival is only 1–2 %. Whereas
among patients at limited stage, median survival is about* Correspondence: wangys@scu.edu.cn
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creativecommons.org/publicdomain/zero/1.0/23 months and 5-year survival is 12–25 % [6–10]. SCLC is
the most aggressive type of lung cancer mainly due to
rapid growth, wide invasion, and fast metastasis [8, 11–13].
Therefore, it is critical to investigate an effective strategy
for SCLC treatment.
It is widely reported that SUMOylation is a post-
translational modification, which is significantly involved
in diverse cellular functions, including genome integrity,
nuclear transport, gene expression, signal transduction,
and cell proliferation and differentiation through modu-
lating protein-protein interactions [14–19]. In addition,
recent data have pointed that cancer is associated with
alterations in SUMOylation [14]. Mechanically, SUMOy-
lation requires three steps of enzymatic reactions todistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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the substrates: activation with the E1 enzyme (SAE1/
SAE2), conjugation with the E2 enzyme (UBC9), and
ligation with E3 ligase. Especially, SAE2 is a critical com-
ponent of the SUMO-activating enzyme which is neces-
sary for SUMO pathway [15, 18–20]. Accumulating
evidence indicates that SUMO pathway is involved in a
variety of cancers [21–30]. A recent study showed that
SAE2 inactivation could be a therapeutic strategy in Myc
overexpression cancers [31]. However, the roles of SAE2
in SCLC, in which c-Myc was widely amplified and
over-expressed [32–40], are still unknown.
Here, we investigated the role of SAE2 in SCLC. We
found higher expression of SAE2 in SCLC than in normal
tissues. Furthermore, we observed that down-regulation of
SAE2 expression in SCLC cells suppressed cell prolifera-
tion, migration, invasion as well as tumor formation and
promoted cell apoptosis. Based on these findings, we con-
cluded that down-regulation of SAE2 expression enhanced
tumor suppression and sensitivity of chemotherapy in
SCLC, and targeting SAE2 may be a new method for pa-
tients with SCLC.
Results
Increased expression of SAE2 in SCLC patients and cell
lines
To investigate the roles of SAE2 in SCLC in which c-
Myc was demonstrated to be widely amplified andFig. 1 SAE2 expression in SCLC tissues and cell lines. a Representative imm
from SCLC patient (n = 20) and normal lung tissues (n = 5). b The expression
c The expression of SAE2 protein in SCLC cell lines (H446, H146, H526, H69, an
experiments (*P < 0.05, **P < 0.01)expressed, we detected SAE2 protein level by immuno-
histochemical staining in the SCLC specimens and the
normal lung tissues. Interestingly, we detected a signifi-
cant elevated expression of SAE2 in SCLC tumor tis-
sues(P < 0.001) (Fig. 1a). Moreover, we analyzed gene
expression of SAE2 from the NCBI GEO database with
23 clinical small cell lung cancer (SCLC) samples from
patients undergoing pulmonary resection and 42 normal
tissue samples including the lung using Affymetrix Hu-
man Genome U133 Plus 2.0 Array (GSE43346). SAE2
was also highly expressed in SCLC compared to the nor-
mal tissues (Additional file 1: Figure S1). The mRNA
and protein level of SAE2 were detected using quantita-
tive real-time PCR and Western blot in several cell lines,
including H446, H526, H69, H146, and BEAS-2B. Both
mRNA expression and protein levels of SAE2 were signifi-
cantly higher in SCLC cell lines compared with normal
cell line (BEAS-2B) (Fig. 1b, c).These results indicated that
SAE2 is highly expressed in SCLC tissues and cell lines.
Inhibition of cell proliferation in H446 cells with SAE2
silence
To investigate the role of SAE2 in SCLC, we firstly estab-
lished H446 cells with stably down-expressing SAE2
(shSAE2-H446) by Plko.1-shSAE2. Cells stably harbored
the corresponding empty Plko.1 vector which was estab-
lished as control (shCtrl-H446). Quantitative real-time
PCR and Western blotting analysis showed that theunohistochemical results of the expression of SAE2 in tumor tissues
of SAE2 mRNA in SCLC cell lines (H446, H146, H526 H69, and BEAS-2B).
d BEAS-2B). Data represent means ± SEM of three independent
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H446 cells (Fig. 2a, b). We further examined the effect of
SAE2 on cell proliferation determined by the MTT assay.
The growth rate revealed that silence of SAE2 significantly
reduced viable cells (Fig. 2c). Consistently, less numbers of
colonies were observed in shSAE2-H446 cells in colony
formation assay (Fig. 2d), and the difference was signifi-
cant (Fig. 2e).These results suggest that silence of SAE2
inhibits the growth of SCLC cell.
Induction of apoptosis in H446 with SAE2 knockdown
To explore the effect of SAE2 deficiency on cell apop-
tosis and cell cycle, apoptosis assay by Annexin V-
FITC/propidium iodide (PI) staining and propidium
iodide (PI) staining were performed. Our results re-
vealed that there were approximately 20 % apoptotic
cells in shSAE2-H446 cells (Fig. 3a, second panel),
compared to only 9.39 % of cells in shCtrl-H446 cells
(Fig. 3a, first panel). Meanwhile, we detected proteins
involved in apoptosis by Western blot. Expression of Bcl-2
was prominently decreased, while Bcl-XL, P53, and P21
were maintained (Fig. 3c). These data indicated thatFig. 2 SAE2 affects the proliferation of SCLC cell line. Knockdown of SAE2
c Growth rate of H446 cells with or without knockdown of SAE2 was determi
experiments. Representative colony images (d) and quantification of colony (e
means ± SD of three independent experiments (**P < 0.01, ***P < 0.001)silence of SAE2 was sufficient to promote apoptosis by de-
creasing the expression of Bcl-2 in H446 cells. In addition,
there was no significant difference in cell cycle of shSAE2-
H446 cells compared with shCtrl-H446 cells after starving
for 24 h, detected by PI staining (Fig. 3d, e). We conclude
that knockdown of SAE2 in SCLC cells increased
apoptosis.
Knockdown of SAE2-inhibited cell invasion and migration
in vitro and tumorigenesis in vivo
We next investigated the effects of SAE2 on cell invasion
and migration. A transwell cell migration assay showed
that knockdown of SAE2 in H446 cells exhibited a sig-
nificant decrease in cell migration ability (Fig. 4a). Fur-
thermore, by using a transwell matrigel cell invasion
assay, we found that the invasion ability of shSAE2-
H446 cells was also significantly reduced (Fig. 4a, b). As
MMP2 and MMP9 were crucial proteins involved in
cancer cell metastasis, we reasoned that SAE2 might
regulate MMP expression in the SCLC. Expression of
MMP2 and MMP9 in shCtrl-H446 cells or shSAE2-
H446 cells were measured by Western blot analysis. Wein H446 cell line confirmed by Western blot (a) and real-time PCR (b).
ned by MTT assay. Data shown are means ± SD of three independent
) are shown with or without knockdown of SAE2. Data are presented as
Fig. 3 SAE2 is associated with apoptosis in SCLC cell line. a Representative FCM result stained by Annexin V-FITC and PI. Annexin V+/PI− and
Annexin V+/PI+ cells were designed as early stage and advanced stage of the apoptotic process. b The flow cytometry (FCM) results are presented
as the percentage of apoptotic cells. The sum of FITC-positive cells in the top right and bottom right quadrants represents the total percentage of
apoptotic cells. c Apoptosis-related protein levels were examined by Western blots using β-actin as a loading control. d Cell cycle analysis was
performed by FCM and e the percentage of the cell population at different cell cycle phases was shown. Each data point represents means ± SD
of three independent experiments (***P < 0.001)
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creased in shSAE2-H446 cells compared with that in
shCtrl-H446 cells (Fig. 4c). These data indicated that si-
lence of SAE2 was sufficient to inhibit invasion and mi-
gration by decreasing the expression of MMP2 and
MMP9 in H446 cells. Furthermore, to test the effects of
knockdown of SAE2 in vivo, shCtrl-H446 cells or
shSAE2-H446 cells were inoculated subcutaneously into
the flanks of nude mice, and the tumorigenesis in mice
was observed for 8 weeks (Fig. 5). As the results shown
in Table 1, the incidence of subcutaneous tumorigenesisin the athymic nude mice harboring shSAE2-H446 cells
was 0/15 at 56 days post-inoculation, whereas 14/15
xenograft were established with shCtrl-H446 cells. These
results demonstrated that knockdown of SAE2 markedly
inhibited tumorigenesis of H446 cells in vivo.
Sensitization of chemotherapy in H446 cell line with SAE2
knockdown
It is widely reported that SCLC is the most aggressive
type of lung cancer mainly due to quickly refractory to
initial therapy. We next investigated whether knockdown
Fig. 4 SAE2 is essential for the migratory and invasive potential of SCLC cells in vitro. a Transwell invasion and migration assays of shCtrl-H446
and shSEA2 H446 tumor cells were performed. b The results are showed as an average of the number of migration/invasion cells from six random
microscopic fields. c MMP2 and MMP9 protein level was measured by Western blot. Each data point represents mean ± SD of three independent
experiments (***P < 0.001)
Fig. 5 Effects of SAE2 on the tumorigenesis of SCLC cells. shCtrl-H446
or shSAE2-H446 cells were inoculated subcutaneously into the flanks of
nude mice. The tumor in mice were observed for 8 weeks (n = 15)
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Cell viability assay for stable cell lines shCtrl-H446 and
shSAE2-H446 were performed after treatment with dif-
ferent concentrations of etoposide and cisplatin for 48
and 72 h, respectively (Fig. 6c, d). Our result showed
that knockdown of SAE2 in H446 significantly reduced
the IC50 of chemotherapeutical agents etoposide (16.65
μM in shSAE2-H446 vs 27.26 μM in shCtrl-H446) and
cisplatin (1.874 μM in shSAE2-H446 vs 2.528 μM in
shCtrl-H446) (Table 2). In our previous study, down-
regulation of SAE2 inhibited cell growth mainly by indu-
cing cell apoptosis, then we examined the apoptosis of
SAE2 down-regulated cells treated with etoposide or cis-
platin and showed that proportion of apoptotic cells was
significantly increased in shSAE2-H446 cells (Fig. 6a, b).
These results suggested that down-regulating SAE2 im-
proved chemosensitivity in SCLC.
Discussion
Although various efforts have been made to improve the
treatment of SCLC, the patient prognosis has not beenTable 1 Effects of down-regulation SAE2 expression on




Fig. 6 Knockdown of SAE2 sensitized chemotherapy in H446 (a). shCtrl-H446 and shSAE2-H446 tumor cells were treated with etoposide (15 μM)
or cisplatin(1.5 μM) for 24 and 48 h, respectively. Cell apoptosis was detected by Annexin V and propidium iodide staining (b). The FCM results
are presented as the percentage of apoptotic cells. Drug concentration–dependent cell survival curves for etoposide (c) for 48 h and cisplatin
(d) for 72 h in shSAE2-H446cells or shCtrl-H446 cells. Each data point represents means ± SD of three independent experiments (*P < 0.05,
**P < 0.01)
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tial E1 activating enzyme for SUMOylation, SAE2 plays
a key role in SUMOylation which is associated with sev-
eral diseases including tumors [41]. Recent reports sug-
gest that SAE2 deregulation induces the development of
hepatocellular carcinoma [42]. Moreover, Kessler, JD
et al. showed that SAE2 inactivation could be a therapeutic
strategy in Myc overexpression cancers [31]. Therefore, we
speculated that SAE2 was important for tumor formation
and progression in SCLC which was characterized withTable 2 IC50 values of chemotherapeutical agents
IC50 value(μM)
Cell line Cisplatin Etoposide
shCtrl-H446 2.528 27.26
shSAE2-H446 1.874 16.65high c-Myc expression. And we discovered an elevated ex-
pression of SAE2 in SCLC tissue and cell lines. We investi-
gated the role of SAE2 in SCLC. Further, we provide the
evidence that SAE2 plays an important role in regulating
cellular proliferation, invasion, and sensitivity of chemo-
therapy in SCLC.
Several reports suggested that SUMOylation modifi-
cation, occurs through a series of enzymatic reactions, is
associated with apoptosis regulation, maintenance of gen-
ome integrity, modulation of subcellular transport, and
transcription [17]. Therefore, the growth inhibition by
knocking down SAE2 was assessed, and we discovered that
selective down-expression of SAE2 significantly inhibit
cell proliferation. Meanwhile, Annexin V-FITC/PI double
staining showed an increased cell apoptosis when SAE2
was knocked down. Bcl-2, an important anti-apoptotic
protein, was accordingly reduced in shSAE2-H446 stable
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in inhibition of cell proliferation. These data suggest that
altered expression of SAE2 is an important contributor to
the development of SCLC. Therefore, we analyzed the
tumorigenesis of H446 with or without knockdown of
SAE2. Xenograft model showed that selected down-
expression of SAE2 significantly decreased tumorigenesis
of H446. As demonstrated that misregulation of sumo
proteins was involved in tumor development [42], our re-
sults suggest that the elevated expression of SAE2 in SCLC
cells might contribute to tumorigenesis. This is likely
due to the fact that SAE2 is a crucial enzyme for
SUMOylation and numerous important proteins, such
as tumor oncoproteins.
SCLC has the tendency for early dissemination and me-
tastases [11]. And increasing data have indicated that
SUMO modifications were critical regulators in cancer-
related metastasis [23, 30, 41]. In our study, cell migration
and invasion assay verified that down-expression of SAE2
inhibited the migratory and invasive properties of SCLC
cells in vitro. MMP-2 and MMP-9 are correlated with in-
vasion and metastasis through degradation of type IV col-
lagen which is principal for the basement membrane [43,
44]. Here, we indicated that expression of MMP-2 and
MMP-9 was decreased in shSAE2-H446 cells, which sug-
gested that SAE2 silence-induced inhibition of SCLC inva-
sion and migration might be related with MMP-2 and
MMP-9. However, the molecular mechanism of shSAE2-
H446-mediated inhibition of the invasion and metastasis
in SCLC needed further research.
Treatment in SCLC is often associated with rapid drug
resistance [5, 11]; therefore, new approaches to improve
the efficiency of chemotherapy are extremely needed to
be developed. Several studies have suggested that small
ubiquitin like modifier SUMOylation is significantly in-
volved in multidrug resistance in several cancers, such
as ovarian carcinoma and hepatocellular carcinoma [26,
45, 46]. Consistently, we observed that down-expression
of SAE2 significantly sensitized cells to cisplatin and eto-
poside in vitro. Annexin V-FITC binding assay proved
that chemotherapy induced increased cell apoptosis in
SAE2 knocked down cells. This may be due to SAE2’s
role in signal transduction pathways including cytokines,
Wnt, NF-κB, and growth factors [18, 42, 47].
Though SAE2 may be a candidate in SCLC treatment,
further study needs to be done, especially considering its
role dependent on Myc-driven cancers. JD Kessler re-
ported that inactivation of SAE2 inhibited tumorigenicity
of Myc-dependent tumors, SUM159 and MDA-MB-231,
whereas MCF7 and SKBR3, both of which were Myc-
independent, were unaffected. In addition, clinical data
showed that expression level of SAE2 correlated with
outcome in patient with Myc-high tumors but not Myc-
low tumors. We also detected the expression of c-Myc inSCLC cells and found that H446, but not H69 and H526,
displayed high expression levels of c-Myc (Additional
file 1: Figure S2). Furthermore, silence of SAE2 with
siRNA in H526 cells did not induce apoptosis (Additional
file 1: Figure S3). This suggests that targeting SAE2 mainly
plays a role in SCLC with high c-Myc expression.
Conclusions
In summary, unprecedentedly, our studies confirmed that
SAE2 was aberrantly overexpressed in SCLC significantly
correlating to tumorigenesis. Meanwhile, knockdown of
SAE2 not only negatively influenced the proliferation, mi-
gration, and invasion of SCLC cells but also facilitated
basal apoptosis and chemotherapy-induced apoptosis.
These findings demonstrate a crucial role of SAE2 in the
progression of SCLC and suggest that SAE2 may serve as




Four human SCLC cell lines (H446, H146, H526, and
H69) and one normal cell line (BEAS-2B) were used in
this study. H446, H146, H526, H69, and BEAS-2B cell
lines were cultured in RPMI-1640 Medium containing
10 % fetal bovine serum with 1 % penicillin/streptomycin
(SIGMA) at 37 °C in a CO2 incubator (5 % CO2). Cells in
exponential growth phase were used for all experiments.
Immunohistochemical staining
All the tumor samples of 20 patients with SCLC and 5
normal lung tissues from West China Hospital were fixed
in 10 % paraformaldehyde, embedded in paraffin, and cut
in 5 μm serial sections. Immunohistochemical staining
was performed using a peroxidase-labeled streptavidin-
biotin technique. Firstly, tissue sections were deparaffi-
nized and rehydrated. Then, sections were boiled in 10
mM sodium citrate buffer (pH 6.0) and maintained at a
sub-boiling temperature for 10 min to retrieve antigenicity
and were treated with 3 % H2O2 in methanol for 10 min
to quench endogenous peroxidase activity. After washing
in 10 mM PBS (pH 7.6), sections were incubated with 10 %
normal mouse serum for SAE2 or rabbit serum (Solarbio
Science and Technology) for c-Myc for 10 min to block
nonspecific antibody binding. Sections were then incubated
with mouse anti-human SAE2 polyclonal antibody (1:100)
or rabbit anti-human c-Myc polyclonal antibody (1:100)
overnight at 4 °C. After washing in PBS, sections were
treated with a 1:100 dilution of biotinylated donkey anti-
mouse IgG for SAE2 or anti-rabbit IgG for 30 min
followed by a streptavidin-peroxidase conjugate for
30 min. A solution of 0.02 % diaminobenzidine hydrochlor-
ide (DAB) containing 0.03 % H2O2 was used as chromogen
to visualize peroxidase activity. The preparations were
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Permount (Thermo Fisher Scientific), and examined by
light microscopy.
Lentiviral vectors mediated SAE2-specific shRNA stable
transfection
Before they were incubated overnight, 293 T cells were
plated at 5 × 106 cells per 100-mm dish. The cells were co-
transfected with 9 μg pLKO.1-vector/pLKO.1-shSAE2,
9 μg psPAX2, and 4.5 μg pMD2.G-VSV-G (at a 2:2:1 ratio).
Virus was harvested at 48 and 72 h post-transfection,
filtered with a 0.45-μm pore size cellulose acetate filter
(Millipore), and infected the H446 cells with the presence
of 8 μg/mL of polybrene. Cells were selected with 0.9
μg/mL puromycin 24 h later.
Western blotting
In brief, cells were washed three times with PBS buffer
and lysed in RIPA lysis buffer (Beyotime) on ice. Total
protein (50 μg/sample) was extracted and separated by 10
% sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE) and then transferred onto polyvinylidene
difluoride (PVDF) membranes (Millipore, USA). Mem-
branes were blocked with 5 % non-fat milk in TBST
(10 mM Tris, pH 7.4150 mM NaCl, and 0.1 % Tween-20)
at room temperature for 1 h. The blotted membranes
were incubated with 1–2 μg/ml of primary antibodies
(Anti-SAE2:ab118404, Anti-Bcl-2:CST#2870S,Anti-Bcl-
XL:ab32370, Anti-P53:ab32049,Anti-P21:ab109199, Anti
MMP2:ab92536, Anti-MMP9:ab3159) diluted in blocking
solution at 4 °C overnight with gentle rocking. After wash-
ing five times with TBST, the membrane was reacted with
the appropriate HRP-conjugated secondary antibody for
1 h at 37 °C. β-actin protein was also determined by using
specific antibody (dilution 1:1000, Cell Signaling Technol-
ogy) as a loading control. After extensive washing with
TBST, proteins were visualized by the enhanced chemilu-
minescence (ECL) detection.
RNA extraction and analysis by quantitative real-time PCR
Total RNA from each cell was extracted with RNA simple
Total RNA Kit (TIANGEN BIOTECH, BEIJING). The
RNA samples were reverse-transcribed into cDNA with
the PrimeScript™ RT reagent Kit (TAKARA). Quantitative
real-time PCR was conducted with Bio-rad CFX manager
and SsoAdvanced SYBR Green Supermix (Bio-rad) as the
detection dye. The primer sequences of PCR were as fol-
lows: SAE2, sense 5′-GATAACAGAGCTG CCCGAAAC-
3′ and anti-sense 5′-ATAACACTCGGTCACACCCTTT-3′,
GAPDH, sense5′GAAGGTGAAGGTCGGAGT-3′ and
antisense 5′-GAAGATGGTGATGGGATTTC-3′. RT-PCR
amplification was performed in 40 cycles with DNA de-
naturation at 95 °C for 5 s and annealing/extension at
60 °C for 20 s. For analysis, GAPDH mRNA was usedto normalize RNA inputs, ΔΔCt values were calculated
and converted to approximate fold change values (2-
ΔΔCt).
Cell proliferation assay
Seeded in 96-well plates were 2 × 103 cells/well. From the
second day to the sixth day, 20 μL MTT (Sigma-Aldrich)
(5 mg/mL) was added to each well, incubated at 37 °C for
4 h, terminated with 150 μL of dimethyl sulfoxide (Sigma-
Aldrich) per well, gently shook for 5 min, and determined
with an ELISA reader (Bio-Rad) at 570 nm. For cell viable
assay, cells were seeded in 96-well plates and exposed to
various concentrations of etoposide (0, 5, 10, 20, 40,
80, and 160 μM) for 48 h or Cisplatin (0, 0.5, 1, 2, 4,
8, 16 μM) for 72 h; MTT assay was used to detect the
chemotherapeutic sensitivity of cells. The concentra-
tion for 50 % of maximal effect (IC50 values) was cal-
culated by GraphPad Prism.
Annexin V-binding assay
Cells were seeded onto 6-well plates at a cell density
of 2 × 105 cells/well; 24 h later, cells were treated with
Etoposide(15 μM) for 24 h or Cisplatin(1.5 μM) for 48
h. Control cells were treated with NS. Then cells were
harvested and apoptosis was analyzed by flow cytome-
try using an FITC Annexin V Apoptosis Detection Kit
I (BD Pharmingen) according to the manufacturer’s
instructions.
Cell cycle analysis
Cells were seeded at 3 × 105 per well in 6-well plates
and cultured with RPMI-1640 Medium non-containing
fetal bovine serum for 24 h. Then cells were harvested
and washed three times with cold PBS. Cells were fixed
in 70 % ice-cold ethanol overnight, washed twice with
PBS, stained with PI/RNase staining buffer (BD Phar-
mingen) at room temperature for 15 min, and detected
by flow cytometer. Data were analyzed using CellQuest
software.
Cell migration assay
This cell migration assay was analyzed using transwell
cell culture chambers (8 μm pore size) (Millipore).
Briefly, cells (1 × 105 /well) were serum starved for 24 h
and placed in the upper chamber of a 24-well transwell
in serum-free medium. RPMI 1640 containing 10 % FBS
as chemoattractant were added to the lower chamber,
and the cells were incubated at 37 °C in a CO2 incubator
(5 % CO2) for 24 h. Then, the filter side of the upper
chamber was cleaned with a cotton swab, fixed with 4 %
formaldehyde for 10 min, and stained with 0.1 % crystal
violet for 20 min. Finally, migrated cells were photo-
graphed under a light microscope and counted in six
random microscopic fields.
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Polycarbonate membranes of transwell chambers were
coated with Matrigel (BD Biosciences) on the upper sur-
face. Cells (3 × 104/well) starved from serum for 24 h
were resuspended in serum-free RPMI1640 and added
to the upper chamber of 24-well transwell. And a
complete RPMI1640 medium was added to the lower
chamber as chemoattractant. The cells were incubated
for 24 h at 37 °C with 5 % CO2. Non-invading cells were
removed with a cotton-tipped swab from the top of the
Matrigel. The invasive cells were photographed and
counted in six random microscopic fields.
RNA interference
siRNA for SAE2 was designed and synthesized by Life
Technologies (Lifetech, China). The sequence of siRNA




CUCGAGUAUACCCUAU-5′. The sequence of negative
control (siCtrl) was also designed by Life Technologies.
H526 cells were plated onto a 6-well plate at 2 × 106/well
and transfected using GeneSilencer transfection Reagent
(Genlantis, CA, USA) according to the manufacturer’s
protocol. Cells were collected after 48 h for further
experiments.
Tumor formation rate following in vivo transplantation
A total of 30 Balb/c nude mice (6 weeks old) were obtained
from the Vital River Laboratory Animal Technology, Beijing,
housed in a specific pathogen free (SPF) environment; 7 days
later, the mice were divided into two groups. The mice were
injected with 1 × 107 cells stably knocked down of SAE2
(shSAE2-H446) and parental pLKO.1-vector (shCtrl-H446)
cells subcutaneously separately from each group. After in-
oculation, mice were housed in a sterile barrier system at
constant temperature (25 ± 2 °C) and humidity (45-50 %).
Tumor formation and growth were observed daily.
Colony formation assay
Cells (single cell suspension) were seeded for colony for-
mation assay in six-well plates at a density of 600 cells/
well. The medium was replaced with fresh medium
every 3 days. After 10 days, cell colonies were fixed and
stained with crystal violet (0.5 % in 20 % methanol). Cell
colonies were photographed under a light microscope
and counted.
Statistical analysis
Statistical analysis of SAE2 expression level of all 20 pa-
tients and 5 controls was performed using SPSS version
19.0 for windows (SPSS Inc) using Mann–Whitney test.
All the other statistical analyses were performed usingthe GraphPad Prism 6.01 software program. Data ana-
lysis was carried out using the one-way ANOVA Tukey
test for multiple groups and t test for two groups ana-
lysis. All data were summarized and presented as means ±
SD or means ± SEM, P < 0.05 were considered to indicate
statistically significant differences.
Additional file
Additional file 1: Supplemental materials. Figure S1. Expression
levels of SAE2 in SCLC. Figure S2. Expression of c-myc in SCLC cells.
Figure S3. Influence of SAE2 on apoptosis in H526 cells.
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